An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biocad
- 07 Sep 2017 Phase of the trial changed from 2 to 2/3.Number of armas has cganged from 3 to4,hence number of planned patient has also changd from 165 to 399.
- 07 Sep 2017 Planned number of patients changed from 165 to 399.
- 07 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2020.